Eli Lilly Global External R&D Director Yetunde Taiwo On Partnering Plans For Discovery Research: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Yetunde Taiwo, Eli Lilly's global external R&D director, is on a global hunt for molecules that can bolster Lilly's research efforts and arm it with novel therapies. Eli Lilly spends more than $3.4 billion on research every year and prides itself on being a pioneer in collaborating with scientists to bring drugs into the market. Over the last two years, Eli Lilly struck research alliances with at least four Indian companies and has increased its activities in Asia (PharmAsia News, Oct 27, 2008). Taiwo sat down with PharmAsia News' India bureau to give a lowdown on Lilly's risk-sharing strategy to shore up its new chemical entities.
You may also be interested in...
Eli Lilly Talks Up Emerging Markets, Especially China, As One Salve For Its Problems
Insisting they are not playing catch up overseas, Eli Lilly executives outlined plans for growing their business in the so-called emerging markets that are now a hot terrain - and a familiar phrase - among the biggest drug makers
Eli Lilly Talks Up Emerging Markets, Especially China, As One Salve For Its Problems
Insisting they are not playing catch up overseas, Eli Lilly executives outlined plans for growing their business in the so-called emerging markets that are now a hot terrain - and a familiar phrase - among the biggest drug makers
Merck's Chief Strategy Officer Mervyn Turner Talks To PharmAsia News About Partnerships And Transformational Research Models
Mervyn J. Turner, Merck's chief strategy officer and senior vice president for emerging markets is entrusted with the responsibility of forging research partnerships with companies across the globe. Turner evaluates pipelines and capabilities of companies that can benefit the core drug discovery functions at Merck's laboratories and as part of that function, he is building partnerships with companies in India such as Ranbaxy, Piramal Healthcare, Orchid and Advinus. On a visit to India recently, Turner sat down with PharmAsia News' India bureau to elaborate on his future ideas.